GlaxoSmithKline's new HIV dual-drug regimen meets phase 3 goal, but analysts want more
admin 14th June 2018 Uncategorised 0GlaxoSmithKline’s ViiV Healthcare already has Juluca, the first complete two-drug HIV therapy, for patients who are virally suppressed. Now, it has new data to back its dual-drug expansion into treatment-naïve patients, but analysts want to see more data before giving their definite thumbs-up.
More: GlaxoSmithKline's new HIV dual-drug regimen meets phase 3 goal, but analysts want more
Source: fierce